Exhibit
No.
|
Description
|
|
Unaudited Condensed Consolidated Interim Financial Statements for the Three Months Ended March 31, 2022.
|
||
Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2022.
|
||
Press Release dated May 11, 2022.
|
IMMUNOCORE HOLDINGS PLC
|
||||
Date:
|
May 11, 2022
|
By:
|
/s/ Bahija Jallal, Ph.D.
|
|
Name
|
Bahija Jallal, Ph.D.
|
|||
Title:
|
Chief Executive Officer
|
Page
|
||
2
|
||
3
|
||
4
|
||
5
|
||
6
|
Three months ended
March 31,
|
||||||||||||
Notes
|
2022
£’000
|
2021
£’000
|
||||||||||
Product revenue, net
|
3 |
7,682
|
—
|
|||||||||
Pre-product revenue, net
|
3 |
2,829
|
—
|
|||||||||
Collaboration revenue
|
3 |
11,963
|
8,270
|
|||||||||
Total revenue
|
22,474
|
8,270
|
||||||||||
Cost of product revenue
|
(248
|
)
|
—
|
|||||||||
Research and development costs
|
(18,581
|
)
|
(19,885
|
)
|
||||||||
Selling and administrative expenses
|
|
(20,106
|
)
|
(20,184
|
)
|
|||||||
Net other operating income / (expense)
|
1
|
(82
|
)
|
|||||||||
Operating loss
|
(16,460
|
)
|
(31,881
|
)
|
||||||||
Finance income
|
10
|
22
|
||||||||||
Finance costs
|
4
|
(1,333
|
)
|
(1,860
|
)
|
|||||||
Non-operating expense
|
(1,323
|
)
|
(1,838
|
)
|
||||||||
Loss before taxation
|
(17,783
|
)
|
(33,719
|
)
|
||||||||
Income tax credit
|
5
|
1,655
|
4,681
|
|||||||||
Loss for the period
|
(16,128
|
)
|
(29,038
|
)
|
||||||||
Other comprehensive income / (loss)
|
||||||||||||
Other comprehensive income / (loss) that is or may be reclassified to profit or loss in subsequent periods:
|
||||||||||||
Exchange differences on translation of foreign operations
|
205
|
(92
|
)
|
|||||||||
Total other comprehensive income / (loss) for the period
|
205
|
(92
|
)
|
|||||||||
Total comprehensive loss for the period
|
(15,923
|
)
|
(29,130
|
)
|
||||||||
Basic and diluted loss per share - £
|
6 |
(0.37
|
)
|
(0.76
|
)
|
Notes
|
March 31,
2022
£’000
|
December 31,
2021
£’000
|
||||||||||
Non-current assets
|
||||||||||||
Property, plant and equipment
|
7,849
|
8,944
|
||||||||||
Right of use assets
|
22,199
|
22,593
|
||||||||||
Other non-current assets
|
5,955
|
4,935
|
||||||||||
Deferred tax asset
|
2,650
|
2,575
|
||||||||||
Total non-current assets
|
38,653
|
39,047
|
||||||||||
Current assets
|
||||||||||||
Inventory
|
496
|
—
|
||||||||||
Trade and other receivables
|
7
|
25,746
|
15,208
|
|||||||||
Tax receivable
|
11,289
|
9,632
|
||||||||||
Cash and cash equivalents
|
205,853
|
237,886
|
||||||||||
Total current assets
|
243,384
|
262,726
|
||||||||||
Total assets
|
282,037
|
301,773
|
||||||||||
Equity
|
||||||||||||
Share capital
|
88
|
88
|
||||||||||
Share premium
|
212,499
|
212,238
|
||||||||||
Foreign currency translation reserve
|
294
|
89
|
||||||||||
Other reserves
|
386,167
|
386,167
|
||||||||||
Share-based payment reserve
|
61,770
|
54,357
|
||||||||||
Accumulated deficit
|
(497,520
|
)
|
(481,392
|
)
|
||||||||
Total equity
|
163,298
|
171,547
|
||||||||||
Non-current liabilities
|
||||||||||||
Interest-bearing loans and borrowings
|
38,370
|
37,226
|
||||||||||
Deferred revenue
|
3
|
2,136
|
6,408
|
|||||||||
Lease liabilities
|
25,043
|
25,355
|
||||||||||
Provisions
|
70
|
57
|
||||||||||
Total non-current liabilities
|
65,619
|
69,046
|
||||||||||
Current liabilities
|
||||||||||||
Trade and other payables
|
9
|
34,695
|
35,436
|
|||||||||
Deferred revenue
|
3
|
17,089
|
24,450
|
|||||||||
Lease liabilities
|
1,294
|
1,255
|
||||||||||
Provisions
|
42
|
39
|
||||||||||
Total current liabilities
|
53,120
|
61,180
|
||||||||||
Total liabilities
|
118,739
|
130,226
|
||||||||||
Total equity and liabilities
|
282,037
|
301,773
|
Notes
|
Share
capital
£’000
|
Share
premium
£’000
|
Foreign
currency
translation
reserve
£’000
|
Share-
based
payment
reserve
£’000
|
Other
reserve
£’000
|
Accumulated
deficit
£’000
|
Total
equity
£’000
|
|||||||||||||||||||||||||
At January 1, 2022
|
88
|
212,238
|
89
|
54,357
|
386,167
|
(481,392
|
)
|
171,547
|
||||||||||||||||||||||||
Loss for the period
|
—
|
—
|
—
|
—
|
—
|
(16,128
|
)
|
(16,128
|
)
|
|||||||||||||||||||||||
Other comprehensive income
|
—
|
—
|
205
|
—
|
—
|
—
|
205
|
|||||||||||||||||||||||||
Total comprehensive income/ (loss) for the period
|
—
|
—
|
205
|
—
|
—
|
(16,128
|
)
|
(15,923
|
)
|
|||||||||||||||||||||||
Exercise of share options
|
—
|
261
|
—
|
—
|
—
|
—
|
261
|
|||||||||||||||||||||||||
Equity-settled share-based payment transactions
|
8
|
—
|
—
|
—
|
7,413
|
—
|
—
|
7,413
|
||||||||||||||||||||||||
At March 31, 2022
|
88
|
212,499
|
294
|
61,770
|
386,167
|
(497,520
|
)
|
163,298
|
Notes
|
Share
capital
£’000
|
Share
premium
£’000
|
Foreign
currency
translation
reserve
£’000
|
Share-
based
payment
reserve
£’000
|
Other
reserve
£’000
|
Accumulated
deficit
£’000
|
Total
equity
£’000
|
|||||||||||||||||||||||||
At January 1, 2021
|
64
|
—
|
163
|
18,821
|
386,167
|
(349,869
|
)
|
55,346
|
||||||||||||||||||||||||
Loss for the period
|
—
|
—
|
—
|
—
|
(29,038
|
)
|
(29,038
|
)
|
||||||||||||||||||||||||
Other comprehensive loss
|
—
|
—
|
(92
|
)
|
—
|
—
|
—
|
(92
|
)
|
|||||||||||||||||||||||
Total comprehensive loss for the period
|
—
|
—
|
(92
|
)
|
—
|
—
|
(29,038
|
)
|
(29,130
|
)
|
||||||||||||||||||||||
Issue of share capital
|
24
|
210,961
|
—
|
—
|
—
|
—
|
210,985
|
|||||||||||||||||||||||||
Equity-settled share-based payment transactions
|
8
|
—
|
325
|
—
|
8,271
|
—
|
—
|
8,596
|
||||||||||||||||||||||||
At March 31, 2021
|
88
|
211,286
|
71
|
27,092
|
386,167
|
(378,907
|
)
|
245,797
|
Three months ended
March 31,
|
||||||||
2022
£’000
|
2021
£’000
|
|||||||
Cash flows from operating activities
|
||||||||
Loss for the period
|
(16,128
|
)
|
(29,038
|
)
|
||||
Adjustments for:
|
||||||||
Equity settled share-based payment expense
|
7,413
|
8,596
|
||||||
Depreciation
|
1,679
|
1,807
|
||||||
Net finance costs
|
1,323
|
1,838
|
||||||
Foreign exchange differences
|
945
|
(368
|
)
|
|||||
Other
|
(1
|
)
|
219
|
|||||
Income tax credit
|
(1,655
|
)
|
(4,681
|
)
|
||||
Working capital adjustments:
|
||||||||
(Increase) / decrease in receivables and other non-current assets
|
(11,489
|
)
|
2,068
|
|||||
(Decrease) / increase in trade and other payables
|
(807
|
)
|
631
|
|||||
Decrease in deferred revenue
|
(11,633
|
)
|
(7,051
|
)
|
||||
Other working capital movements
|
(480
|
)
|
—
|
|||||
Net cash used in operating activities
|
(30,833
|
)
|
(25,979
|
)
|
||||
Cash flows from investing activities
|
||||||||
Proceeds from sale of property, plant and equipment
|
5
|
—
|
||||||
Purchase of property, plant and equipment
|
(138
|
)
|
(220
|
)
|
||||
Proceeds from investment in sub-leases
|
—
|
245
|
||||||
Net cash flows (used in) / generated by investing activities
|
(133
|
)
|
25
|
|||||
Cash flows from financing activities
|
||||||||
Gross proceeds from issue of share capital
|
—
|
226,528
|
||||||
Costs from issue of share capital
|
—
|
(15,543
|
)
|
|||||
Exercise of share options
|
261
|
—
|
||||||
Interest paid on non-current interest-bearing loan
|
(838
|
)
|
(810
|
)
|
||||
Repayment of lease liabilities
|
(755
|
)
|
(802
|
)
|
||||
Net cash flows (used in) / generated by financing activities
|
(1,332
|
)
|
209,373
|
|||||
(Decrease) / increase in cash and cash equivalents
|
(32,298
|
)
|
183,419
|
|||||
Net foreign exchange difference on cash held
|
265
|
(52
|
)
|
|||||
Cash and cash equivalents at beginning of the year
|
237,886
|
129,716
|
||||||
Cash and cash equivalents at end of the period
|
205,853
|
313,083
|
For the three months ended
March 31,
|
||||||||
2022
£’000
|
2021
£’000
|
|||||||
Product revenue, net
|
7,682
|
—
|
||||||
Pre-product revenue, net
|
2,829
|
—
|
||||||
Total revenue from sale of therapies
|
10,511
|
—
|
||||||
Collaboration revenue
|
||||||||
GSK
|
—
|
3,370
|
||||||
Eli Lilly
|
7,361
|
—
|
||||||
Genentech
|
4,602
|
4,900
|
||||||
Total collaboration revenue
|
11,963
|
8,270
|
||||||
Total revenue
|
22,474
|
8,270
|
For the three months ended
March 31,
|
||||||||
2022
|
2021
|
|||||||
|
£’000
|
|
£’000
|
|||||
United States
|
7,682
|
—
|
||||||
Europe
|
2,829
|
—
|
||||||
Total revenue from the sale of therapies
|
10,511
|
—
|
For the three months ended
March 31,
|
||||||||
2022
£’000
|
2021
£’000
|
|||||||
Interest expense on lease liabilities
|
429
|
439
|
||||||
Interest expense on financial liabilities measured at amortized cost
|
904
|
1,421
|
||||||
1,333
|
1,860
|
For the three months ended
March 31,
|
||||||||
2022
|
2021
|
|||||||
Loss for the period (£’000s)
|
(16,128
|
)
|
(29,038
|
)
|
||||
Basic and diluted weighted average number of shares
|
43,865,799
|
38,451,332
|
||||||
Basic and diluted loss per share (£) (1)
|
(0.37
|
)
|
(0.76
|
)
|
March 31,
2022
£’000
|
December 31,
2021
£’000
|
|||||||
Trade receivables
|
16,795
|
6,047
|
||||||
Other receivables
|
2,355
|
1,470
|
||||||
Prepayments and accrued income
|
6,596
|
7,691
|
||||||
25,746
|
15,208
|
For the three months ended
March 31
|
||||||||
|
2022
$
|
2021
$
|
||||||
Weighted average exercise price
|
24.95
|
26.00
|
||||||
Weighted average fair value
|
15.27
|
16.16
|
March 31,
2022
£’000
|
December 31,
2021
£’000
|
|||||||
Trade payables
|
6,074
|
7,499
|
||||||
Other taxation and social security
|
733
|
532
|
||||||
Accruals
|
27,680
|
27,382
|
||||||
Other payables
|
208
|
23
|
||||||
34,695
|
35,436
|
• |
KIMMTRAK (tebentafusp-tebn), our ImmTAC molecule
targeting an HLA-A*02:01 gp100 antigen, is our first approved product. The FDA and the EC have approved KIMMTRAK (tebentafusp) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma, or mUM.
KIMMTRAK demonstrated monotherapy activity and achieved the primary endpoint of superior overall survival in a randomized Phase 3 clinical trial in patients with previously untreated mUM against the investigator’s choice of treatment. The
OS Hazard Ratio (HR) in the intent-to-treat population favored tebentafusp, HR=0.51 (95% CI: 0.37, 0.71); p< 0.0001, over investigator’s choice (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine).
|
• |
Tebentafusp regulatory submissions have been
submitted in additional regulatory agencies outside of the United States and European Union requesting marketing authorization of tebentafusp for the treatment of mUM. The United Kingdom’s Medicines and Healthcare Regulatory Agency, or
MHRA, Health Canada, and the Australian Government of Health have each accepted the submission of an MAA. There are currently over 130 patients in the UK and EU enrolled in the early access program.
|
• |
Tebentafusp is also being developed for the
treatment of metastatic cutaneous melanoma, or mCM. In 2021, we presented data from Phase 1b trial in mCM at the Society for Immunotherapy of Cancer, or SITC, at the 36th Annual Meeting. Preliminary evidence of KIMMTRAK
(tebentafusp-tebn) clinical activity in mCM patients who had prior anti-PD(L)1 therapy, currently an unmet medical need, included 1-year overall survival, or OS, rate of 76%. We anticipate initiating a mCM randomized clinical trial with and
without an anti-PD(L)1 therapy in the fourth quarter of 2022.
|
• |
IMC-C103C, our ImmTAC molecule targeting an
HLA-A*02:01 MAGE-A4 antigen, is currently being evaluated in a first-in-human, Phase 1/2 dose escalation clinical trial in patients with solid tumor cancers including non-small-cell lung cancer, or NSCLC, gastric, head and neck, ovarian and
synovial sarcoma. In December 2021, we reported initial Phase 1 data from the trial at the European Society of Medical Oncology Immuno-Oncology Congress. IMC-C103C demonstrated a manageable safety profile and clinical activity with
confirmed durable responses in ovarian cancer and a confirmed durable response in head and neck squamous cell carcinoma. We initiated an expansion arm in high-grade serous ovarian carcinoma at 140 micrograms/week. We anticipate reporting
additional data from the Phase 1 trial in the fourth quarter of 2022.
|
• |
IMC-F106C, our ImmTAC molecule targeting an optimal
HLA-A*02:01 PRAME antigen is currently being evaluated in a first-in-human, Phase 1/2 dose escalation clinical trial in patients with multiple solid tumor cancers including NSCLC, SCLC, endometrial, ovarian, cutaneous melanoma, and breast
cancers. As of December 31, 2021, we have enrolled 39 patients in the Phase 1 study. Early pharmacodynamic data indicate that IMC-F106C monotherapy is demonstrating biological activity at the doses currently under evaluation. We anticipate
reporting Phase 1 initial data from the trial in the third quarter of 2022.
|
• |
IMC-I109V, our ImmTAV molecule targeting a
conserved hepatitis B virus, or HBV, envelope antigen, is our most advanced ImmTAV program and is currently being evaluated in a Phase 1/2 clinical trial in patients with chronic HBV who are non-cirrhotic, hepatitis B e-Antigen
negative, and virally suppressed on chronic nucleot(s)ide analogue therapy. Our goal is to develop a functional cure for HBV. We initiated dosing in our Phase 1 single ascending dose, or SAD, trial in the second quarter of 2021.
|
• |
IMC-M113V, our ImmTAV molecule targeting a human
immunosuppression virus, or HIV, gag antigen bispecific TCR molecule, is currently in pre-clinical development. Our goal is to develop a functional cure for HIV. Our clinical trial application in the United Kingdom was accepted in December
2021, and we anticipate dosing the first patient in this trial during the second quarter of 2022. We plan to then expand the trial to Europe later in 2022.
|
• |
after reviewing trial results, our collaboration partners may abandon projects that might previously have been believed to be promising;
|
• |
we, our collaboration partners, or regulators may suspend or terminate clinical trials if the participating subjects or patients are being exposed to unacceptable health risks;
|
• |
our potential products may not have the desired effects or may include undesirable side effects or other characteristics that preclude regulatory approval or limit their commercial use if approved;
|
• |
manufacturers may not meet the necessary standards for the production of the product candidates or may not be able to supply the product candidates in a sufficient quantity
|
• |
regulatory authorities may find that our clinical trial design or conduct does not meet the applicable approval requirements; and
|
• |
safety and efficacy results in various human clinical trials reported in scientific and medical literature may not be indicative of results we obtain in our clinical trials.
|
Three Months Ended March 31,
|
||||||||||||
2022
|
2021
|
|||||||||||
$
|
’000
|
£
|
’000
|
£
|
’000
|
|||||||
Product revenue, net
|
10,103
|
7,682
|
—
|
|||||||||
Pre-product revenue, net
|
3,721
|
2,829
|
—
|
|||||||||
Collaboration revenue
|
15,734
|
11,963
|
8,270
|
|||||||||
Total revenue
|
29,558
|
22,474
|
8,270
|
|||||||||
Cost of product revenue
|
(326
|
)
|
(248
|
)
|
—
|
|||||||
Research and development expenses
|
(24,438
|
)
|
(18,581
|
)
|
(19,885
|
)
|
||||||
Selling and administrative expenses
|
(26,443
|
)
|
(20,106
|
)
|
(20,184
|
)
|
||||||
Net other operating income / (expense)
|
1
|
1
|
(82
|
)
|
||||||||
Operating loss
|
(21,648
|
)
|
(16,460
|
)
|
(31,881
|
)
|
||||||
Finance income
|
13
|
10
|
22
|
|||||||||
Finance costs
|
(1,753
|
)
|
(1,333
|
)
|
(1,860
|
)
|
||||||
Non-operating expense
|
(1,740
|
)
|
(1,323
|
)
|
(1,838
|
)
|
||||||
Loss before taxes
|
(23,388
|
)
|
(17,783
|
)
|
(33,719
|
)
|
||||||
Income tax credit
|
2,177
|
1,655
|
4,681
|
|||||||||
Loss for the period
|
(21,211
|
)
|
(16,128
|
)
|
(29,038
|
)
|
Three Months Ended March 31,
|
||||||||||||
2022
|
2021
|
|||||||||||
$
|
’000
|
£
|
’000
|
£
|
’000
|
|||||||
Product revenue, net
|
10,103
|
7,682
|
—
|
|||||||||
Pre-product revenue, net
|
3,721
|
2,829
|
—
|
|||||||||
Total revenue from sale of therapies
|
13,824
|
10,511
|
—
|
|||||||||
Collaboration revenue
|
||||||||||||
GSK
|
—
|
—
|
3,370
|
|||||||||
Eli Lilly
|
9,681
|
7,361
|
—
|
|||||||||
Genentech
|
6,053
|
4,602
|
4,900
|
|||||||||
Total collaboration revenue
|
15,734
|
11,963
|
8,270
|
|||||||||
Total revenue
|
29,558
|
22,474
|
8,270
|
Three Months Ended March 31,
|
||||||||||||
2022
|
2021
|
|||||||||||
$
|
’000
|
£
|
’000
|
£
|
’000
|
|||||||
External research and development expenses:
|
||||||||||||
Tebentafusp
|
6,071
|
4,616
|
8,069
|
|||||||||
IMC-F106C (PRAME)
|
2,609
|
1,984
|
1,245
|
|||||||||
IMC-C103C (MAGE-A4)
|
1,986
|
1,510
|
1,074
|
|||||||||
IMC-I109V(HBV)
|
613
|
466
|
734
|
|||||||||
Other programs
|
1,331
|
1,012
|
2,190
|
|||||||||
Research expenses
|
146
|
111
|
72
|
|||||||||
Total external research and development expenses
|
12,756
|
9,699
|
13,384
|
|||||||||
Internal research and development expenses:
|
||||||||||||
Headcount related expenses
|
8,584
|
6,527
|
5,238
|
|||||||||
Laboratory consumables
|
1,597
|
1,214
|
888
|
|||||||||
Laboratory equipment expenses
|
1,395
|
1,061
|
374
|
|||||||||
Other
|
105
|
80
|
1
|
|||||||||
Total internal research and development expenses
|
11,681
|
8,882
|
6,501
|
|||||||||
Total research and development expenses
|
24,437
|
18,581
|
19,885
|
Three Months Ended March 31,
|
||||||||||||
March 31, 2022
|
March 31, 2021
|
|||||||||||
$
|
’000
|
£
|
’000
|
£
|
’000
|
|||||||
Share-based payment charge
|
8,521
|
6,479
|
7,940
|
|||||||||
Other employee related expenses
|
5,387
|
4,096
|
3,270
|
|||||||||
Selling and commercial costs
|
8,712
|
6,624
|
1,187
|
|||||||||
Legal and professional fees
|
2,288
|
1,740
|
2,933
|
|||||||||
Depreciation
|
1,411
|
1,073
|
1,808
|
|||||||||
Other expenses
|
3,255
|
2,475
|
2,217
|
|||||||||
Foreign exchange (gains) / losses
|
(3,131
|
)
|
(2,381
|
)
|
829
|
|||||||
Total selling and administrative expenses
|
26,443
|
20,106
|
20,184
|
Three Months Ended March 31,
|
||||||||||||
2022
|
2022
|
2021
|
||||||||||
$
|
’000
|
£
|
’000
|
£
|
’000
|
|||||||
|
||||||||||||
Cash and cash equivalents at beginning of year
|
312,868
|
237,886
|
129,716
|
|||||||||
Net cash flows used in operating activities
|
(40,552
|
)
|
(30,833
|
)
|
(25,979
|
)
|
||||||
Net cash flows (used in) / from investing activities
|
(175
|
)
|
(133
|
)
|
25
|
|||||||
Net cash flows (used in) / from financing activities
|
(1,752
|
)
|
(1,332
|
)
|
209,373
|
|||||||
Net foreign exchange difference on cash held
|
349
|
265
|
(52
|
)
|
||||||||
Cash and cash equivalents at end of period
|
270,738
|
205,853
|
313,083
|
• |
execute our sales and marketing strategy of KIMMTRAK in the United States, Europe and elsewhere;
|
• |
create additional infrastructure to support our operations as a public company listed in the United States and our product development and planned future commercialization efforts;
|
• |
continue to advance our clinical trials and the development of our pre-clinical programs;
|
• |
continue to invest in our soluble TCR platforms to conduct research to identify novel technologies;
|
• |
change or add additional suppliers;
|
• |
add additional infrastructure to our quality control, quality assurance, legal, compliance and other groups to support our operations as we progress product candidates toward commercialization;
|
• |
seek to attract and retain skilled personnel;
|
• |
seek marketing approvals and reimbursement for our product candidates;
|
• |
establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;
|
• |
seek to identify and validate additional product candidates;
|
• |
acquire or in-license other product candidates and technologies;
|
• |
maintain, protect, defend, enforce and expand our intellectual property portfolio; and
|
• |
experience any delays, interruptions or encounter issues with any of the above, including any delays or other impacts as a result of the COVID-19 pandemic.
|
Three Months Ended March 31,
|
||||||||||||
2022
|
2021
|
|||||||||||
$
|
’000
|
£
|
’000
|
£
|
’000
|
|||||||
Product revenue, net
|
10,103
|
7,682
|
—
|
|||||||||
Pre-product revenue, net
|
3,721
|
2,829
|
—
|
|||||||||
Collaboration revenue
|
15,734
|
11,963
|
8,270
|
|||||||||
Total revenue
|
29,558
|
22,474
|
8,270
|
|||||||||
Cost of product revenue
|
(326
|
)
|
(248
|
)
|
—
|
|||||||
Research and development expenses
|
(24,438
|
)
|
(18,581
|
)
|
(19,885
|
)
|
||||||
Selling and administrative expenses
|
(26,443
|
)
|
(20,106
|
)
|
(20,184
|
)
|
||||||
Net other operating income / (expense)
|
1
|
1
|
(82
|
)
|
||||||||
Operating loss
|
(21,648
|
)
|
(16,460
|
)
|
(31,881
|
)
|
||||||
Finance income
|
13
|
10
|
22
|
|||||||||
Finance costs
|
(1,753
|
)
|
(1,333
|
)
|
(1,860
|
)
|
||||||
Non-operating expense
|
(1,740
|
)
|
(1,323
|
)
|
(1,838
|
)
|
||||||
Loss before taxes
|
(23,388
|
)
|
(17,783
|
)
|
(33,719
|
)
|
||||||
Income tax credit
|
2,177
|
1,655
|
4,681
|
|||||||||
Loss for the period
|
(21,211
|
)
|
(16,128
|
)
|
(29,038
|
)
|
Three Months Ended March 31,
|
||||||||||||
2022
|
2022
|
2021
|
||||||||||
$
|
’000
|
£
|
’000
|
£
|
’000
|
|||||||
|
||||||||||||
Cash and cash equivalents at beginning of year
|
312,868
|
237,886
|
129,716
|
|||||||||
Net cash flows used in operating activities
|
(40,552
|
)
|
(30,833
|
)
|
(25,979
|
)
|
||||||
Net cash flows (used in) / from investing activities
|
(175
|
)
|
(133
|
)
|
25
|
|||||||
Net cash flows (used in) / from financing activities
|
(1,752
|
)
|
(1,332
|
)
|
209,373
|
|||||||
Net foreign exchange difference on cash held
|
349
|
265
|
(52
|
)
|
||||||||
Cash and cash equivalents at end of period
|
270,738
|
205,853
|
313,083
|
March 31,
2022
£’000
|
December 31,
2021
£’000
|
|||||||
Non-current assets
|
||||||||
Property, plant and equipment
|
7,849
|
8,944
|
||||||
Right of use assets
|
22,199
|
22,593
|
||||||
Other non-current assets
|
5,955
|
4,935
|
||||||
Deferred tax asset
|
2,650
|
2,575
|
||||||
Total non-current assets
|
38,653
|
39,047
|
||||||
Current assets
|
||||||||
Inventory
|
496
|
—
|
||||||
Trade and other receivables
|
25,746
|
15,208
|
||||||
Tax receivable
|
11,289
|
9,632
|
||||||
Cash and cash equivalents
|
205,853
|
237,886
|
||||||
Total current assets
|
243,384
|
262,726
|
||||||
Total assets
|
282,037
|
301,773
|
||||||
Equity
|
||||||||
Share capital
|
88
|
88
|
||||||
Share premium
|
212,499
|
212,238
|
||||||
Foreign currency translation reserve
|
294
|
89
|
||||||
Other reserves
|
386,167
|
386,167
|
||||||
Share-based payment reserve
|
61,770
|
54,357
|
||||||
Accumulated deficit
|
(497,520
|
)
|
(481,392
|
)
|
||||
Total equity
|
163,298
|
171,547
|
||||||
Non-current liabilities
|
||||||||
Interest-bearing loans and borrowings
|
38,370
|
37,226
|
||||||
Deferred revenue
|
2,136
|
6,408
|
||||||
Lease liabilities
|
25,043
|
25,355
|
||||||
Provisions
|
70
|
57
|
||||||
Total non-current liabilities
|
65,619
|
69,046
|
||||||
Current liabilities
|
||||||||
Trade and other payables
|
34,695
|
35,436
|
||||||
Deferred revenue
|
17,089
|
24,450
|
||||||
Lease liabilities
|
1,294
|
1,255
|
||||||
Provisions
|
42
|
39
|
||||||
Total current liabilities
|
53,120
|
61,180
|
||||||
Total liabilities
|
118,739
|
130,226
|
||||||
Total equity and liabilities
|
282,037
|
301,773
|